Mark Samuels, Chief Executive of the British Generic Manufacturers Association (BGMA), urges EU and UK to put patients above politics in solving medicine supply challenges for Northern Ireland.
List view / Grid view
The Competition and Markets Authority (CMA) announced the EU Court of Justice agreed that GSK had paid to delay other competitors entering the UK paroxetine generics market.
Price caps and government regulations will not lower US healthcare costs, instead supply chain and drug pricing reforms are required, says a brief by medical economist.
The FDA has issued a statement to promote the development of complex generic drugs to ensure access for patients and healthy drug competition...
A Europe-wide policy covering the generic pharmaceuticals market would significantly boost growth in the sector, reveals a new report from Frost & Sullivan...